A Phase II Study of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
The purpose of this study is to test the effectiveness, safety, and tolerability of the drug
combination carboplatin, paclitaxel, and bevacizumab(Avastin) in patients with advanced
stage endometrial carcinoma. This is a phase II,open label,single center study. Patients
will receive carboplatin, paclitaxel, and bevacizumab in an outpatient center by intravenous
administration. The primary objectives is to study the progression free survival at 24
months after initiation of treatment and to determine the toxicity profile of the drug
combinations. The secondary objectives are to estimate the overall survival and tumor
response for this group of patients.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess the progression free survival and determine toxicity profile as assessed by NCI Common Toxicity Criteria for Adverse Events 3.0
24 monthes
No
David O'Malley, MD
Principal Investigator
The Ohio State University Division of Gyn Oncology
United States: Food and Drug Administration
2007CO008
NCT00513786
August 2007
August 2012
Name | Location |
---|---|
Ohio State University-Division of Gyn Oncology | Columbus, Ohio 43210 |